BCWM
CADL icon

Bartlett & Co Wealth Management’s Candel Therapeutics CADL Stock Holding History

Bartlett & Co Wealth Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.5K Buy
+3,520
New +$19.2K ﹤0.01% 778

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bartlett & Co Wealth Management's CADL Position: Q1 2026 in Review

Bartlett & Co Wealth Management opened a new position in Candel Therapeutics (CADL) in Q1 2026: 3,520 shares worth $26.5K. The stake represents ﹤0.01% of the portfolio and ranks #778 among its holdings.

114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Bartlett & Co Wealth Management held 3,520 shares of Candel Therapeutics worth $26.5K as of Q1 2026.
  • Candel Therapeutics was a new Bartlett & Co Wealth Management position in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Bartlett & Co Wealth Management's portfolio in Q1 2026, its #778 holding.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.